Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
This is a two-part, Phase 1 open label, multi-center, dose escalation study of
CEP-37250/KHK2804 as monotherapy in subjects with advanced solid tumors who no longer respond
to standard therapy or for whom no standard therapy is available.